Immunome, Inc. (NASDAQ:IMNM) Receives Average Rating of “Buy” from Analysts

Immunome, Inc. (NASDAQ:IMNM) has earned an average rating of “Buy” from the seven ratings firms that are presently covering the firm, MarketBeat reports. Seven investment analysts have rated the stock with a buy recommendation. The average 12 month target price among analysts that have issued a report on the stock in the last year is $29.80.

Several equities analysts recently weighed in on the stock. JPMorgan Chase & Co. initiated coverage on shares of Immunome in a research report on Tuesday, April 30th. They set an “overweight” rating and a $24.00 price objective on the stock. Piper Sandler initiated coverage on shares of Immunome in a report on Friday, May 31st. They set an “overweight” rating and a $27.00 price target on the stock. Guggenheim began coverage on shares of Immunome in a report on Monday, April 15th. They issued a “buy” rating and a $35.00 price objective for the company. Finally, Wedbush reaffirmed an “outperform” rating and issued a $33.00 price target on shares of Immunome in a research report on Tuesday, May 14th.

Immunome Price Performance

NASDAQ IMNM opened at $16.05 on Tuesday. The company has a 50 day simple moving average of $16.08 and a 200-day simple moving average of $16.58. The firm has a market capitalization of $962.52 million, a price-to-earnings ratio of -2.13 and a beta of 1.85. Immunome has a 52-week low of $4.76 and a 52-week high of $30.96.

Immunome (NASDAQ:IMNM) last issued its earnings results on Tuesday, May 14th. The company reported ($0.34) EPS for the quarter, beating analysts’ consensus estimates of ($0.80) by $0.46. Immunome had a negative return on equity of 37.33% and a negative net margin of 1,829.44%. The firm had revenue of $1.03 million for the quarter, compared to the consensus estimate of $4.00 million. On average, analysts predict that Immunome will post -1.45 EPS for the current year.

Insider Buying and Selling at Immunome

In other Immunome news, Director Jean Jacques Bienaime purchased 2,000 shares of the business’s stock in a transaction dated Tuesday, May 21st. The stock was bought at an average cost of $13.57 per share, for a total transaction of $27,140.00. Following the completion of the acquisition, the director now directly owns 9,615 shares in the company, valued at $130,475.55. The purchase was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders own 8.60% of the company’s stock.

Hedge Funds Weigh In On Immunome

Several large investors have recently bought and sold shares of the stock. Acadian Asset Management LLC bought a new position in shares of Immunome during the 3rd quarter worth about $414,000. Cerity Partners LLC bought a new position in Immunome during the fourth quarter valued at about $656,000. Emfo LLC acquired a new position in Immunome in the 4th quarter valued at approximately $633,000. Jump Financial LLC bought a new stake in shares of Immunome in the 4th quarter worth approximately $172,000. Finally, Mayo Clinic bought a new stake in shares of Immunome during the fourth quarter valued at approximately $1,161,000. 44.58% of the stock is currently owned by institutional investors and hedge funds.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.